Search Results - "GULATI, Mridu"

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis by Damsky, William, Wang, Alice, Kim, Daniel J., Young, Bryan D., Singh, Katelyn, Murphy, Michael J., Daccache, Joseph, Clark, Abigale, Ayasun, Ruveyda, Ryu, Changwan, McGeary, Meaghan K., Odell, Ian D., Fazzone-Chettiar, Ramesh, Pucar, Darko, Homer, Robert, Gulati, Mridu, Miller, Edward J., Bosenberg, Marcus, Flavell, Richard A., King, Brett

“…Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes…”
Get full text

Occupational lung diseases: from old and novel exposures to effective preventive strategies by Cullinan, Paul, Prof, Muñoz, Xavier, MD, Suojalehto, Hille, MD, Agius, Raymond, Prof, Jindal, Surinder, Prof, Sigsgaard, Torben, Prof, Blomberg, Anders, Prof, Charpin, Denis, MPH, Annesi-Maesano, Isabella, Prof, Gulati, Mridu, MD, Kim, Yangho, Prof, Frank, Arthur L, Prof, Akgün, Metin, Prof, Fishwick, David, Prof, de la Hoz, Rafael E, MD, Moitra, Subhabrata, Dr

“…Summary Occupational exposure is an important, global cause of respiratory disease. Unlike many other non-communicable lung diseases, the proximal causes of…”
Get full text

Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease by Swaminathan, Aparna C, McFatrich, Molly, Mkumba, Laura, Wright, Lauren, Redlich, Carrie A, Snyder, Laurie D, Reeve, Bryce B, Patel, Divya, Gulati, Mridu

“…Identification of exposures in patients with interstitial lung diseases (ILDs) is essential for diagnosis and management and can be facilitated through the use…”
Get full text

Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis by Tzouvelekis, Argyris, Herazo‐Maya, Jose D., Slade, Martin, Chu, Jen‐hwa, Deiuliis, Giuseppe, Ryu, Changwan, Li, Qin, Sakamoto, Koji, Ibarra, Gabriel, Pan, Hongyi, Gulati, Mridu, Antin‐Ozerkis, Danielle, Herzog, Erica L., Kaminski, Naftali

“…Background and objective Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and variable clinical course. Although matrix…”
Get full text

Persistent Exertional Intolerance After COVID-19 by Singh, Inderjit, Joseph, Phillip, Heerdt, Paul M., Cullinan, Marjorie, Lutchmansingh, Denyse D., Gulati, Mridu, Possick, Jennifer D., Systrom, David M., Waxman, Aaron B.

“…Some patients with COVID-19 who have recovered from the acute infection after experiencing only mild symptoms continue to exhibit persistent exertional…”
Get full text

Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study by Ryan, Sarah M., Mroz, Margaret M., Herzog, Erica L., Ryu, Changwan, Fingerlin, Tasha E., Maier, Lisa A., Gulati, Mridu

“…Sarcoidosis is a granulomatous disorder thought to be caused by exposures in genetically susceptible individuals. This study investigated whether specific…”
Get full text

Newly Recognized Occupational and Environmental Causes of Chronic Terminal Airways and Parenchymal Lung Disease by Sauler, Maor, MD, Gulati, Mridu, MD, MPH

“…With the introduction of new materials and changes in manufacturing practices, occupational health investigators continue to uncover associations between novel…”
Get full text

Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease by Zhou, Yang, He, Chuan Hua, Herzog, Erica L, Peng, Xueyan, Lee, Chang-Min, Nguyen, Tung H, Gulati, Mridu, Gochuico, Bernadette R, Gahl, William A, Slade, Martin L, Lee, Chun Geun, Elias, Jack A

“…Hermansky-Pudlak syndrome (HPS) comprises a group of inherited disorders caused by mutations that alter the function of lysosome-related organelles. Pulmonary…”
Get full text

Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis by Sun, Huanxing, Zhu, Yangyang, Pan, Hongyi, Chen, Xiaosong, Balestrini, Jenna L., Lam, TuKiet T., Kanyo, Jean E., Eichmann, Anne, Gulati, Mridu, Fares, Wassim H., Bai, Hanwen, Feghali‐Bostwick, Carol A., Gan, Ye, Peng, Xueyan, Moore, Meagan W., White, Eric S., Sava, Parid, Gonzalez, Anjelica L., Cheng, Yuwei, Niklason, Laura E., Herzog, Erica L.

“…Objective Fibrocytes are collagen‐producing leukocytes that accumulate in patients with systemic sclerosis (SSc; scleroderma)–related interstitial lung disease…”
Get full text

Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages by Murray, Lynne A, Rosada, Rogerio, Moreira, Ana Paula, Joshi, Amrita, Kramer, Michael S, Hesson, David P, Argentieri, Rochelle L, Mathai, Susan, Gulati, Mridu, Herzog, Erica L, Hogaboam, Cory M

“…Macrophages promote tissue remodeling but few mechanisms exist to modulate their activity during tissue fibrosis. Serum amyloid P (SAP), a member of the…”
Get full text

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort by Todd, Jamie L., Neely, Megan L., Overton, Robert, Mulder, Hillary, Roman, Jesse, Lasky, Joseph A., de Andrade, Joao A., Gulati, Mridu, Huang, Howard, Leonard, Thomas B., Hesslinger, Christian, Noth, Imre, Belperio, John A., Flaherty, Kevin R., Palmer, Scott M.

“…Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease with a variable clinical course. Biomarkers that predict patient outcomes are…”
Get full text

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib by Rahaghi, Franck, Belperio, John A, Fitzgerald, John, Gulati, Mridu, Hallowell, Robert, Highland, Kristin B, Huie, Tristan J, Kim, Hyun J, Kolb, Martin, Lasky, Joseph A, Southern, Brian D, Swigris, Jeffrey J, de Andrade, Joao A

“…Purpose: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF…”
Get full text

Non-steroidal treatment of cardiac sarcoidosis: A systematic review by Gallegos, Cesia, Oikonomou, Evangelos K., Grimshaw, Alyssa, Gulati, Mridu, Young, Bryan D., Miller, Edward J.

“…The treatment of active cardiac sarcoidosis (CS) usually involves immunosuppressive therapy, with the goal of preventing inflammation-induced scar formation…”
Get full text

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort by Todd, Jamie L., Neely, Megan L., Overton, Robert, Mulder, Hillary, Roman, Jesse, Lasky, Joseph A., de Andrade, Joao A., Gulati, Mridu, Huang, Howard, Leonard, Thomas B., Hesslinger, Christian, Noth, Imre, Belperio, John A., Flaherty, Kevin R., Palmer, Scott M.

Get full text

Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome by Singh, Inderjit, Leitner, Brooks P., Wang, Yiwei, Zhang, Hanming, Joseph, Phillip, Lutchmansingh, Denyse D., Gulati, Mridu, Possick, Jennifer D., Damsky, William, Hwa, John, Heerdt, Paul M., Chun, Hyung J.

“…Approximately 50% of patients who recover from the acute SARS‐CoV‐2 experience Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. The…”
Get full text

Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis by Murray, Lynne A, Habiel, David M, Hohmann, Miriam, Camelo, Ana, Shang, Huilan, Zhou, Yang, Coelho, Ana Lucia, Peng, Xueyan, Gulati, Mridu, Crestani, Bruno, Sleeman, Matthew A, Mustelin, Tomas, Moore, Meagan W, Ryu, Changwan, Osafo-Addo, Awo D, Elias, Jack A, Lee, Chun G, Hu, Buqu, Herazo-Maya, Jose D, Knight, Darryl A, Hogaboam, Cory M, Herzog, Erica L

“…The chronic progressive decline in lung function observed in idiopathic pulmonary fibrosis (IPF) appears to result from persistent nonresolving injury to the…”
Get full text

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study by Strykowski, Rachel, Patel, Divya C, Neto, Manny Ribeiro, Hena, Kerry M, Gulati, Mridu, Maier, LIsa A, Patterson, Karen

“…IntroductionRespiratory infections are ubiquitous. The COVID-19 pandemic has refocused our attention on how morbid and potentially fatal they can be, and how…”
Get full text

The World Trade Center Residents' Respiratory Health Study: New-Onset Respiratory Symptoms and Pulmonary Function by Reibman, Joan, Lin, Shao, Hwang, Syni-An A., Gulati, Mridu, Bowers, James A., Rogers, Linda, Berger, Kenneth I., Hoerning, Anne, Gomez, Marta, Fitzgerald, Edward F.

“…The destruction of the World Trade Center (WTC) on 11 September 2001 in New York City resulted in the massive release of pulverized dust and combustion…”
Get full text

Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing by Singh, Inderjit, Joseph, Phillip, Heerdt, Paul M, Cullinan, Marjorie, Lutchmansingh, Denyse D, Gulati, Mridu, Possick, Jennifer D, Systrom, David M, Waxman, Aaron B

“…Some patients with COVID-19 who have recovered from the acute infection after experiencing only mild symptoms continue to exhibit persistent exertional…”
Get full text

COVID‐19 as an occupational disease by Carlsten, Christopher, Gulati, Mridu, Hines, Stella, Rose, Cecile, Scott, Kenneth, Tarlo, Susan M., Torén, Kjell, Sood, Akshay, Hoz, Rafael E.

“…The impact of coronavirus disease 2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus 2 permeates all aspects of society worldwide…”
Get full text